NRSN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeuroSense Therapeutics Ltd (NRSN) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment at this time. While there is potential in its ALS treatment pipeline and positive analyst sentiment, the technical indicators are bearish, financial performance is weak, and there are no immediate catalysts to justify an entry point now.
The technical indicators are bearish. The MACD histogram is negative and expanding downward, RSI is neutral at 33.344, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 0.764 and resistance at 0.993.
The company is advancing its ALS treatment pipeline with PrimeC, supported by positive Phase 2b trial results and plans for a Phase 3 trial. Analyst sentiment is positive, with a Buy rating and a $3 price target from Roth Capital.
The financial performance is weak, with no revenue, a significant drop in net income (-100% YoY), and a negative EPS (-0.19). Technical indicators suggest a bearish trend, and there are no significant insider or hedge fund trading trends.
In Q4 2024, the company reported no revenue growth (0% YoY), a net income drop of -100% YoY, and a significant EPS decline of -74.32% YoY. Gross margin remained at 0%.
Roth Capital initiated coverage with a Buy rating and a $3 price target, citing optimism about PrimeC's potential in ALS treatment and long-term revenue projections of $1.5B by 2038.
